Evidence map›Paper›PMID 31665113›Full record

ReviewClinical chemistry and laboratory medicine2020

Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges.

Klára Ščupáková, Benjamin Balluff, Caitlin Tressler, Tobi Adelaja, Ron M A Heeren, Kristine Glunde, Gökhan Ertaylan

Abstract readReview
In one paragraph

Review in Clinical chemistry and laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Quantitative mass spectrometry imaging: therapeutics & biomolecules.Chemical communications (Cambridge, England) · 2024
    Review
  19. Review
  20. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Klára ŠčupákováMaastricht MultiModal Molecular Imaging Institute (M4I), University of Maastricht, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-9726-3565
Benjamin BalluffMaastricht MultiModal Molecular Imaging Institute (M4I), University of Maastricht, Maastricht, The Netherlands.
Caitlin TresslerRussell H. Morgan Department of Radiology and Radiological Science, Division of Cancer Imaging Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tobi AdelajaRussell H. Morgan Department of Radiology and Radiological Science, Division of Cancer Imaging Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ron M A HeerenMaastricht MultiModal Molecular Imaging Institute (M4I), University of Maastricht, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-6533-7179
Kristine GlundeRussell H. Morgan Department of Radiology and Radiological Science, Division of Cancer Imaging Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gökhan ErtaylanUnit Health, Flemish Institute for Technological Research (VITO), Mol, Belgium.

Funding

Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
Hypoxia-derived molecular MSI signatures to predict breast cancer outcomeR01CA213492 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE, HEEREN, RON · 2017 to 2021
$2.1M
Molecular studies of the MR-detectable oncometabolite glycerophosphocholineR01CA213428 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE · 2017 to 2021
$1.9M
NCI NIH HHS R01 CA213428NCI NIH HHS R01 CA213492NCI NIH HHS T32 CA193145
6 · The paper itself

Abstract

Mass spectrometry (MS) is the workhorse of metabolomics, proteomics and lipidomics. Mass spectrometry imaging (MSI), its extension to spatially resolved analysis of tissues, is a powerful tool for visualizing molecular information within the histological context of tissue. This review summarizes recent developments in MSI and highlights current challenges that remain to achieve molecular imaging at the cellular level of clinical specimens. We focus on matrix-assisted laser desorption/ionization (MALDI)-MSI. We discuss the current status of each of the analysis steps and remaining challenges to reach the desired level of cellular imaging. Currently, analyte delocalization and degradation, matrix crystal size, laser focus restrictions and detector sensitivity are factors that are limiting spatial resolution. New sample preparation devices and laser optic systems are being developed to push the boundaries of these limitations. Furthermore, we review the processing of cellular MSI data and images, and the systematic integration of these data in the light of available algorithms and databases. We discuss roadblocks in the data analysis pipeline and show how technology from other fields can be used to overcome these. Finally, we conclude with curative and community efforts that are needed to enable contextualization of the information obtained.

Indexed as

AnimalsHumansSingle-Cell AnalysisSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionizationdata analysisdata integration and interpretationhistopathologymass spectrometry imagingmolecular analysisspatial resolution

Identifiers

PMID31665113
PMCPMC9867918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.